Oricell Therapeutics has now raised over $100 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public. The Shanghai-based company secured backing from the likes ...
Sovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
With biotech firms caught in the crosshairs of Trump's tariffs, the levy could prove to be a boon for domestic producers but ...
U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re ...
HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry ...
Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience. Shanghai-based Fosun is putting down 60 ...
Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors China's healthcare sector has been drawing offshore capital to Hong Kong-listed stocks ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the 'Stock ...
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results